Last reviewed · How we verify
Antiplatelet therapy (AP)
Antiplatelet therapy inhibits platelet aggregation to prevent thrombotic events by blocking platelet activation pathways.
Antiplatelet therapy inhibits platelet aggregation to prevent thrombotic events by blocking platelet activation pathways. Used for Acute coronary syndrome, Secondary prevention of myocardial infarction, Ischemic stroke prevention.
At a glance
| Generic name | Antiplatelet therapy (AP) |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Drug class | Antiplatelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Antiplatelet agents work through various mechanisms—commonly by inhibiting cyclooxygenase (aspirin), blocking ADP receptors (clopidogrel, ticagrelor), or inhibiting phosphodiesterase—to reduce platelet clumping and thrombus formation. This prevents blood clots that can lead to myocardial infarction, stroke, and stent thrombosis in cardiovascular disease.
Approved indications
- Acute coronary syndrome
- Secondary prevention of myocardial infarction
- Ischemic stroke prevention
- Peripheral arterial disease
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
Key clinical trials
- Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial (PHASE3)
- Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets (PHASE3)
- Restart TICrH AP Pilot Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: